Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.54
+$0.02 · +0.44%
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Previous close
$4.54
+$0.02 · +0.44%
Regular session · ET · Market data may be delayed.
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Day range
Current $4.54
52-week range
Current $4.54
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
61
Undervalued
Sentiment
56
Mixed
Risk
52
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Day range
Current $4.54
52-week range
Current $4.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (AUD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | 5.44M AUD | 4.02M AUD | 3.92M AUD | 5.12M AUD |
| Cost of goods sold | 113.01K AUD | 127.52K AUD | 214.3K AUD | 285.07K AUD | 364.67K AUD |
| Gross profit | −113.01K AUD | 5.31M AUD | 3.8M AUD | 3.63M AUD | 4.76M AUD |
| Research and development | 17.24M AUD | 14.4M AUD | 18.64M AUD | 13.2M AUD | 14.75M AUD |
| Selling, general, and administrative | 10.44M AUD | 5.48M AUD | 4.76M AUD | 5.04M AUD | 5.51M AUD |
| Operating expenses | 27.69M AUD | 19.89M AUD | 23.41M AUD | 18.24M AUD | 20.26M AUD |
| Interest income | 1.68M AUD | 446.29K AUD | 268.42K AUD | 16.44K AUD | 2.5K AUD |
| Depreciation and amortization | 113.01K AUD | 28.31K AUD | 35.34K AUD | 37.85K AUD | 54.21K AUD |
| Operating income | −27.8M AUD | −14.57M AUD | −19.6M AUD | −14.64M AUD | −15.5M AUD |
| Net income | −22.89M AUD | −12.15M AUD | −19.12M AUD | −13.81M AUD | −12.85M AUD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
54.19% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 9, 2023 | 1:10 | — | — |
Stock split | Mar 24, 2016 | 1:6 | — | — |
Effective Jan 9, 2023
1:10
Effective Mar 24, 2016
1:6
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
